The evolving tale of immunomodulatory drugs and cereblon

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The immunomodulatory drugs (IMiDs), of which thalidomide was the first in class, have had a complex therapeutic history. Although these drugs are now widely used to treat multiple myeloma, the precise molecular mechanism of action of these agents has remained elusive. The finding that IMiDs bind cereblon, with subsequent activation of E3-ubiquitin ligase activity and degradation of the key transcription factors IKZF1 and IKZF3, has provided insight into these drugs but leaves many questions unanswered.

Original languageEnglish (US)
Pages (from-to)538-541
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number5
StatePublished - Sep 17 2014
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The evolving tale of immunomodulatory drugs and cereblon'. Together they form a unique fingerprint.

Cite this